Total Funding
21
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
239296
Pieris Pharmaceuticals is a clinical-stage biotechnology company applying its proprietary.
Acquired by 
Palvella Therapeutics
Karin Felderer: Director, Head of Technical DevelopmentPast Role: MorphoSys, Associate Director / Laboratory Leader - Protein Production
Arne Skerra: Founder
About the Company
Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company applying its proprietary Anticalin® technology to create differentiated drugs that can help patients suffering from cancer, severe asthma, anemia and other medical conditions with a high unmet medical need.
Anticalins are recombinantly engineered versions of lipocalins, human
proteins that naturally bind, store and transport a wide spectrum of molecules. Our libraries of more than 100 billion different Anticalins can virtually bind to any target of interest.
